Table 1.
Patient and tumor characteristics.
| Age at diagnosis | Years | |
| Median (IQR) | 67 (61,73) | |
| Range | 44–88 | |
| Pretreatment PSA | ng/mL | |
| Mean (SD) | 8.1 (7.7) | |
| Median (IQR) | 5.7 (4.4,8.3) | |
| Pretreatment PSA | Number of patients | Percent |
| <10 ng/mL | 115 | 81 |
| 10–20 ng/mL | 19 | 13 |
| >20 ng/mL | 8 | 6 |
| T-stage | Number of patients | Percent |
| T1c | 106 | 75 |
| T2a | 19 | 13 |
| >T2a | 17 | 12 |
| Gleason score | Number of patients | Percent |
| 5–6 | 76 | 53 |
| 7 | 54 | 38 |
| 8+ | 12 | 9 |
| Risk Group (3) | Number of patients | Percent |
| Low | 61 | 43 |
| Intermediate | 63 | 44 |
| High | 18 | 13 |
| Risk group (5) | Number of patients | Percent |
| Very low | 28 | 20 |
| Low | 33 | 23 |
| Favorable intermediate | 50 | 35 |
| Unfavorable intermediate | 13 | 9 |
| High | 18 | 13 |
| Dose group | Number of patients | Percent |
| Low | 112 | 79 |
| High | 30 | 21 |
| Hormone treatment | Number of patients | Percent |
| No ADT | 102 | 72 |
| ADT | 40 | 28 |